

Kidney Tumor Program



Cincinnati Children's is a major referral center for children, adolescents and young adults with newly diagnosed, advanced, rare and relapsed kidney cancers. Our physicians and researchers have dedicated their careers to developing new treatments, improving disease outcomes and enhancing the quality of life for patients and their families who are dealing with these cancers.

CONTACT US

For patient referrals and non-urgent consultation during business hours, contact the program directly at:

Phone: **1-888-987-7997**

International Phone:
Phone: **+001-513-636-3100**
international@cchmc.org

www.cincinnatichildrens.org

COLLABORATIVE, MULTIDISCIPLINARY CARE FOR CHILDREN WITH KIDNEY TUMORS

When patients and families come to the Kidney Tumor Program for the first time, they meet with a team of kidney cancer specialists for an extensive evaluation. The team includes pediatric oncologists, surgeons, radiologists and a radiation oncologist, among others. Together these experts develop a personalized treatment plan that is based on their clinical experience and perspectives from the most up-to-date research.

These specialists continue to collaborate throughout the child's course of treatment, and provide referring physicians with regular updates to ensure coordinated care.

Among the many treatment options we offer are:

- Chemotherapy
- Proton therapy and traditional radiation therapy
- Surgery, including partial nephrectomy using intraoperative ultrasound techniques
- Radiofrequency ablation
- Novel biologic therapies
- Immunotherapies
- New drug therapies offered through clinical trials
- High-dose chemotherapy with blood and marrow transplantation

ADVANCED THERAPIES FOR HIGH-RISK TUMORS

Cincinnati Children's offers standard of care therapies and a comprehensive phase 1 and 2 clinical research portfolio. When a child's kidney tumor does not respond to standard therapy, we look to other options, including experimental protocols, stem cell rescue and immune therapy. Some of our advanced treatments are available through national research studies, and others are not available anywhere else. This means our patients may have early access to new anticancer therapies, sometimes years before these therapies become widely available.

TUMORS WE TREAT

- Wilms tumor
- Renal cell carcinoma (RCC) including translocation RCC
- Rhabdoid tumors
- Clear cell sarcoma
- Renal angiomyolipoma
- Other rarer renal tumors



Cincinnati Children's is ranked #3 in cancer.

TREATMENT TEAM

Medical Director, Kidney Tumor Program

James I. Geller, MD

Pediatric Nephrology

Stuart Goldstein, MD

Pediatric Oncology, Survivorship

Rajaram Nagarajan, MD, MS

Pediatric Surgery

Alexander Bondoc, MD

Meera Kotagal, MD, MPH

Greg M. Tiao, MD

Radiation Oncology

Luke E. Pater, MD

Ralph Vatner, MD

Pediatric Radiology

Ethan A. Smith, MD

Andrew Trout, MD

Alex Towbin, MD

Pathology

Sarangarajan Ranganathan, MD

Kate VandenHeuvel, MD

For urgent issues, or to speak with the specialist on call 24/7, call the Physician Priority Link® at 1-888-987-7997.

For international inquiries, call +001-513-636-3100 or email international@cchmc.org.

INTERNATIONALLY RECOGNIZED LEADERS IN KIDNEY TUMOR RESEARCH

Physicians and researchers in the Kidney Tumor Program provide leadership at the national and international level, working with their colleagues at Cincinnati Children's and around the world to develop innovative treatments for children with high-risk disease. Areas of research include:

- Novel drug therapies
- New pathways to potential drug targets for Wilms tumors, translocation RCC and rhabdoid tumors
- Factors that affect tumor growth
- Molecular signaling in renal tumors
- Advanced genetic profiling technologies to better understand renal tumors

Cincinnati Children's maintains the international tumor registry for translocation RCC, which includes the development of new tumor models for biology studies and anticancer drug testing. (www.TRRI.org)

Extensive clinical research initiatives

James I. Geller, MD, medical director of the Kidney Tumor Program, is an internationally recognized expert in kidney tumor therapy and next-generation anticancer drug development.

Dr. Geller has served in leadership roles on the national Children's Oncology Group (COG) renal tumor committee since 2009, currently as Committee Chair, and represents the COG on the target and agent prioritization committee for the Pediatric MATCH Trial. He has led the COG renal committee in developmental therapeutics (new drug development) for the last 15 years. He is the COG lead for Harmonica, a joint initiative of the COG renal tumor committee and the International Society of Pediatric Oncology Renal Tumor Study Group to advance clinical effectiveness research.

Dr. Geller leads all three of the COG research studies for high-risk pediatric kidney tumors, which target translocation renal cell carcinoma (Chair, AREN1721), relapsed and anaplastic Wilms tumor (Chair, AREN1921), and rhabdoid tumors (Co-Chair, AREN2021). He also serves as Vice Chair of the COG Renal Tumor Biobanking and Risk Stratification Protocol (AREN03B2), and mentors several COG renal tumor committee 'young investigators'.

Other physician-researchers at Cincinnati Children's are integrally involved in efforts to better understand kidney tumors and improve patient outcomes. This includes pediatric nephrologist **Stuart Goldstein, MD**, director of the Cincinnati Children's Center for Acute Care Nephrology. Dr. Goldstein is nationally regarded for his work related to acute kidney injury, and contributes his expertise to several kidney cancer trials at Cincinnati Children's.

Two pediatric surgeons contribute to clinical research efforts as well. **Meera Kotagal, MD, MPH**, leads two kidney cancer studies. One is exploring new treatment models for children in Uganda, and the other is evaluating on the potential benefits of partial nephrectomy in children with renal cancer. **Alexander Bondoc, MD**, performs kidney transplants at Cincinnati Children's and is developing patient-derived xenografts using human kidney tumor samples. These will provide in vivo models for the study of tumor biology and adaptation, and new drug development.

Radiation oncologist **Luke Pater, MD**, pediatric radiologist **Ethan Smith, MD**, and **pathologist Kate VandenHeuvel** also participate in clinical research projects, sharing their expertise on the COG renal tumor committee and its research protocols and testing new approaches to diagnosing and treating renal cancers.

Laboratory-based research focusing on single cell RNA profiling

Developmental biologist **Steve Potter, PhD**, leads the hospital's basic research program in renal cancer. His work with single cell RNA profiling is helping researchers better understand kidney tumor pathophysiology, resistance clones and signaling pathways. He serves on several national kidney cancer research committees.